These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 17675938)

  • 1. [Therapeutic management of extensive bronchiolo-alveolar adenocarcinoma: chemotherapy or inhibitors of epidermal growth factor receptor tyrosine kinase?].
    Cadranel J; Wislez M; Gounant V; Lavolé A; Antoine M; Milleron B
    Rev Pneumol Clin; 2007 Jun; 63(3):147-54. PubMed ID: 17675938
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Bronchiolar-alveolar carcinoma: From concept to innovative therapeutic strategies].
    Wislez M; Lavolé A; Gounant V; Antoine M; Cadranel J
    Presse Med; 2011 Apr; 40(4 Pt 1):389-97. PubMed ID: 21419590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [EGFR tyrosine kinase inhibitors as a targeted therapy for bronchioloalveolar carcinoma of the lung: a case report of a clinically prompt and intensive response and literature review].
    Svoboda M; Fabian P; Slabý O; Stanková M; Lakomý R; Nemecek R; Vyzula R
    Klin Onkol; 2010; 23(4):224-30. PubMed ID: 20806820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib.
    Miller VA; Riely GJ; Zakowski MF; Li AR; Patel JD; Heelan RT; Kris MG; Sandler AB; Carbone DP; Tsao A; Herbst RS; Heller G; Ladanyi M; Pao W; Johnson DH
    J Clin Oncol; 2008 Mar; 26(9):1472-8. PubMed ID: 18349398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of thoracic radiotherapy in patients with stage IIIB-IV epidermal growth factor receptor-mutant lung adenocarcinomas who received and responded to tyrosine kinase inhibitor treatment.
    Yen YC; Hsu HL; Chang JH; Lin WC; Chang YC; Chang CL; Chow JM; Yuan KS; Wu ATH; Wu SY
    Radiother Oncol; 2018 Oct; 129(1):52-60. PubMed ID: 29703499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A report of two bronchioloalveolar carcinoma cases which were rapidly improved by treatment with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 ("Iressa").
    Yano S; Kanematsu T; Miki T; Aono Y; Azuma M; Yamamoto A; Uehara H; Sone S
    Cancer Sci; 2003 May; 94(5):453-8. PubMed ID: 12824893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IFCT-0401 Trial: a phase II study of gefitinib administered as first-line treatment in advanced adenocarcinoma with bronchioloalveolar carcinoma subtype.
    Cadranel J; Quoix E; Baudrin L; Mourlanette P; Moro-Sibilot D; Morere JF; Souquet PJ; Soria JC; Morin F; Milleron B;
    J Thorac Oncol; 2009 Sep; 4(9):1126-35. PubMed ID: 19574932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic therapy of bronchioloalveolar carcinoma: results of the first IASLC/ASCO consensus conference on bronchioloalveolar carcinoma.
    Kris MG; Giaccone G; Davies A; Fukuoka M; Garfield DH; Jassem J; Quoix EA; Sandler AB; Scagliotti GV; Van Meerbeeck JP; West H
    J Thorac Oncol; 2006 Nov; 1(9 Suppl):S32-6. PubMed ID: 17409999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short-term gefitinib treatment brought about a long-term regression of bronchioloalveolar carcinoma without EGFR gene alterations: a case report.
    Kijima T; Suzuki M; Ueda K; Minami S; Takeda Y; Goya S; Matsuoka H; Kumagai T; Yoshida M; Osaki T; Tachibana I; Yokota S; Kawase I
    Oncol Res; 2007; 16(10):489-95. PubMed ID: 18196873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Response to gefitinib in bronchioloalveolar carcinoma in the absence of EGFR mutation.
    Taja-Chayeb L; Candelaria M; Brom R; Trejo-Becerril C; Meza F; Duenas-Gonzalez A
    Lung Cancer; 2005 Nov; 50(2):259-63. PubMed ID: 16009451
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The salvage therapy in lung adenocarcinoma initially harbored susceptible EGFR mutation and acquired resistance occurred to the first-line gefitinib and second-line cytotoxic chemotherapy.
    Yang CJ; Hung JY; Tsai MJ; Wu KL; Liu TC; Chou SH; Lee JY; Hsu JS; Huang MS; Chong IW
    BMC Pharmacol Toxicol; 2017 May; 18(1):21. PubMed ID: 28486985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
    Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
    Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bronchioloalveolar carcinoma: a model for investigating the biology of epidermal growth factor receptor inhibition.
    Gandara DR; West H; Chansky K; Davies AM; Lau DH; Crowley J; Gumerlock PH; Hirsch FR; Franklin WA
    Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4205s-4209s. PubMed ID: 15217959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prompt control of bronchorrhea in patients with bronchioloalveolar carcinoma treated with gefitinib (Iressa).
    Milton DT; Kris MG; Gomez JE; Feinstein MB
    Support Care Cancer; 2005 Jan; 13(1):70-2. PubMed ID: 15558327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Leukocyte Telomere Length and Clinical Outcomes of Advanced Lung Adenocarcinoma Patients with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Treatment.
    Li J; Zhang L; Zhu H; Pan W; Zhang N; Li Y; Yang M
    DNA Cell Biol; 2018 Nov; 37(11):903-908. PubMed ID: 30277797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of tyrosine kinase inhibitors in lung cancer.
    Ansari J; Palmer DH; Rea DW; Hussain SA
    Anticancer Agents Med Chem; 2009 Jun; 9(5):569-75. PubMed ID: 19519298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Erlotinib after failure of gefitinib in patients with advanced non-small cell lung cancer previously responding to gefitinib.
    Vasile E; Tibaldi C; Chella A; Falcone A
    J Thorac Oncol; 2008 Aug; 3(8):912-4. PubMed ID: 18670311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study.
    Hirsch FR; Varella-Garcia M; McCoy J; West H; Xavier AC; Gumerlock P; Bunn PA; Franklin WA; Crowley J; Gandara DR;
    J Clin Oncol; 2005 Oct; 23(28):6838-45. PubMed ID: 15998906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of bronchoalveolar carcinoma.
    Patel JD
    Clin Lung Cancer; 2004 Dec; 6 Suppl 1():S43-7. PubMed ID: 15638957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L.
    Urata Y; Katakami N; Morita S; Kaji R; Yoshioka H; Seto T; Satouchi M; Iwamoto Y; Kanehara M; Fujimoto D; Ikeda N; Murakami H; Daga H; Oguri T; Goto I; Imamura F; Sugawara S; Saka H; Nogami N; Negoro S; Nakagawa K; Nakanishi Y
    J Clin Oncol; 2016 Sep; 34(27):3248-57. PubMed ID: 27022112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.